Lium, operating as Subnet 51 on the Bittensor network, recorded $2.7 million in GPU rental spending from 2,394 customers over the past 31 days, marking an 87% increase month-over-month. This spending pace projects to an annualized revenue of $34.6 million, driven by both new and existing customers increasing usage. The decentralized GPU cloud primarily serves developers through command line, SDK, or API, accounting for 77.7% of rentals. Overall, Bittensor subnets are approaching $70 million in yearly revenue, signaling growing real-dollar demand for decentralized GPU resources despite ongoing emission subsidies.
The story on Bittensor subnets' revenue growth provides context for readers. For those tracking major cryptocurrencies on Pluang, 12 out of 50 rose while 37 fell today. Notable movers include BNB at Rp11.643.523 with a 1-day change of -4.34% and Pluang order activity of 35% Sell / 65% Buy, BAT at Rp2.133 with -4.18% change and 80% Sell / 20% Buy activity, and ETH at Rp35.600.048 with -3.88% change and 17% Sell / 83% Buy activity. This data is as of Nov 13, 2026 17:21 WIB.
The Philippines solar energy market is projected to grow from 5.43 GW in 2026 to 23.35 GW by 2032, with a CAGR of 27.46%. Growth is fueled by declining costs of solar panels and installation, government-backed renewable energy auctions, and increasin...
Equinor ASA shares will trade ex-dividend on the Oslo Stock Exchange starting November 13, 2026, for the second quarter of 2026. The declared dividend amount is $0.39 per share, payable in USD. This means investors buying shares from this date will n...
China Eastern Airlines signed 23 procurement agreements worth $540 million with 15 suppliers from eight countries at the 9th China International Import Expo in Shanghai. The deals cover aircraft engines, aviation materials, jet fuel, and in-flight ca...
Eramet announced a €500 million share capital increase through a rights issue, offering 6 new shares for every 5 existing shares at €14.49 each. The proceeds will be used to reduce the company's debt and strengthen its balance sheet as part of a prev...
Pasithea Therapeutics announced positive Phase 1/1b results for PAS-004, showing significant reductions in cutaneous neurofibromas (cNF) size by up to 71% with continued treatment and early activity in plexiform neurofibromas (PN). The drug demonstra...
